reports
Newron Pharmaceuticals SPA: 2 directors
Two Directors at Newron Pharmaceuticals SPA bought 9,999 shares at 6.901EUR. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
EQS-News: Newron presents 2024 financial results and provides 2025 out...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Annual Report Newron presents 2024 financial results and provides 2025 outlook 01.04.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron presents 2024 financial results and provides 2025 outlook Milan, Italy, April 1, 2025, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its f...
EQS-News: Newron gibt Geschäftsergebnisse 2024 und Ausblick 2025 bekan...
EQS-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Jahresbericht Newron gibt Geschäftsergebnisse 2024 und Ausblick 2025 bekannt 01.04.2025 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. .awlist1_1743435681_108711 { list-style:none; counter-set:awlistcounter1 } .awlist1_1743435681_108711 li:before { content:'2.' counter(awlistcounter1) '.'; counter-increment:awlistcounter1 } Newron gibt Geschäftsergebnisse 2024 und Ausblick 2025 bekannt Mailand, Italien – 1. April 2025, 07:00 Uhr MESZ – Newron Pharmaceuticals S.p.A....
EQS-News: Newron proposes renowned biopharma company founder and entre...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Personnel Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman 24.03.2025 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman Expected to succeed Dr. Ulrich Köstlin who has notified Newron of his intention to retire after 12 years of service as Chairman of its Board of Directors, effective fol...
EQS-News: Newron schlägt renommierten Biopharma-Firmengründer und -Unt...
EQS-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Personalie Newron schlägt renommierten Biopharma-Firmengründer und -Unternehmer Dr. Chris Martin zur Wahl als unabhängiger Präsident des Verwaltungsrats vor 24.03.2025 / 17:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Newron schlägt renommierten Biopharma-Firmengründer und -Unternehmer Dr. Chris Martin zur Wahl als unabhängiger Präsident des Verwaltungsrats vor Soll die Nachfolge von Dr. Ulrich Köstlin antreten, der Newron über seine Absicht informiert hat, nach zwölf Ja...
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th A...
MILAN, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)-- (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will participate in a fireside chat at the 37th Annual ROTH Conference on Monday, March 17 at 11:30 a.m. PDT. A live audio webcast of the fireside chat can be accessed on the ROTH Conference website . About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for pa...
Newron and Myung In Pharm Announce License Agreement for evenamide in ...
MILAN, Italy & MORRISTOWN, New Jersey & SEOUL, Republic of Korea--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, and Myung In Pharm Co. Ltd. (“Myung In Pharm”), South Korea’s leading CNS specialist pharmaceutical company, today announced that they have entered into a license agreement to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, an add-on therapy for ...
EQS-News: Newron and Myung In Pharm announce license agreement for eve...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Agreement Newron and Myung In Pharm announce license agreement for evenamide in South Korea 09.01.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron and Myung In Pharm announce license agreementfor evenamide in South Korea Myung In Pharm to develop, manufacture and commercialize evenamide in South Korea Myung In Pharm to contribute 10% of patients to Newron’s pivotal Phase III trial for evenamide, and share global development costs Newron will receive upfront paymen...
EQS-News: Newron und Myung In Pharm geben Lizenzvereinbarung für Evena...
EQS-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Vereinbarung Newron und Myung In Pharm geben Lizenzvereinbarung für Evenamide in Südkorea bekannt 09.01.2025 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Newron und Myung In Pharm geben Lizenzvereinbarung für Evenamidein Südkorea bekannt Myung In Pharm wird Evenamide in Südkorea entwickeln, herstellen und vermarkten Myung In Pharm wird 10% der Patienten für die zulassungsrelevante Phase-III-Studie von Newron für Evenamide beisteuern und sich an den globalen Entwickl...
- Sean Conroy
Newron Pharmaceuticals - Evenamide licence agreement in Japan
Newron has entered into a licence agreement with EA Pharma, a subsidiary of Eisai, to develop, manufacture and commercialise evenamide, Newron’s proprietary modulator of the excessive release of glutamate for the treatment of schizophrenia. The transaction covers Japan and other designated Asian territories, meeting management’s target of securing a deal in Q424. Newron will receive an upfront payment of €44m, up to €73m in contributions to development and milestones, and will be eligible to tie...
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce Licens...
MILAN & MORRISTOWN, N.J. & TOKYO--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, and EA Pharma Co., Ltd. (Head Office, Chuo-ku, Tokyo, Japan; President, Hidenori Yabune; “EA Pharma”), a subsidiary of Eisai Co., Ltd., today announced that they have entered into a license agreement to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and ...
EQS-News: Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) annou...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Agreement Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories 13.12.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories Newron will receive up to a maximum of €117 million from an upfront payment, development milestones and commercialization milestones, and up to do...
EQS-News: Newron und EA Pharma (Tochtergesellschaft von Eisai Co., Ltd...
EQS-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Vereinbarung Newron und EA Pharma (Tochtergesellschaft von Eisai Co., Ltd.) geben Lizenzvereinbarung für Evenamide in Japan und weiteren Regionen Asiens bekannt 13.12.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Newron und EA Pharma (Tochtergesellschaft von Eisai Co., Ltd.) geben Lizenzvereinbarung für Evenamide in Japan und weiteren Regionen Asiens bekannt Newron erhält insgesamt bis zu EUR 117 Mio. aus Abschlags- und Meilensteinzahlungen für die Entwicklung u...
- Sean Conroy
Newron Pharmaceuticals - Moving full steam towards pivotal studies
Newron Pharmaceuticals’ H124 results reflect a period of positive traction for lead clinical asset evenamide, with stellar clinical data as an add-on treatment in schizophrenia, building a strong foundation for the upcoming, potentially pivotal Phase III programme (study 017). While the Phase III trial will initially focus on treatment-resistant schizophrenia (TRS), we note the likelihood of the trial expanding to cover patients with poorly managed symptoms, as evaluated in the prior Phase II/II...
Newron presents H1 2024 results and provides business update
MILAN--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the half year ended June 30, 2024, and provided an update on its business activities. Highlights H1 2024: Evenamide Reported positive final one-year results from study 014/015, a Phase II open label trial evaluating evenamide as an add-on therapy to a single antipsychotic in patients with...
EQS-News: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2...
EQS-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Halbjahresergebnis Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2024 und gibt ein Update zum Geschäftsverlauf 19.09.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2024 und gibt ein Update zum Geschäftsverlauf Mailand, Italien, 19. September 2024, 07:00 MESZ –Newron Pharmaceuticals S.p.A. („Newron”, SIX: NWRN, XETRA: NP5), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neua...
EQS-News: Newron presents H1 2024 results and provides business update
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Half Year Results Newron presents H1 2024 results and provides business update 19.09.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron presents H1 2024 results and provides business update Milan, Italy, September 19, 2024, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its fina...
- Sean Conroy
Newron Pharmaceuticals - Evenamide road to registration and beyond
Newron hosted an investor day (25 June) featuring three key opinion leaders (KOLs) who highlighted evenamide’s unique mechanism at the site of pathology, offering durable responses and addressing unmet need despite the >40 available treatments for schizophrenia. Evenamide has a robust track record in clinical studies to date. Notably, the results of study 015 in treatment-resistant schizophrenia (TRS) saw 25% of patients achieve remission, and, more recently, the results from study 008A (poorly ...
EQS-News: Newron Pharmaceuticals reports on its 2024 Investor Day in N...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous Newron Pharmaceuticals reports on its 2024 Investor Day in New York City 25.06.2024 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Newron Pharmaceuticals reports on its 2024 Investor Day in New York City Clinical results and new findings of mechanism of action indicate evenamide would be uniquely effective in patients with treatment resistant schizophrenia Leading schizophrenia experts predict earlier use of evenamide would benefit patients with inadequate res...
EQS-News: Newron Pharmaceuticals berichtet vom Investorentag 2024 in N...
EQS-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Sonstiges Newron Pharmaceuticals berichtet vom Investorentag 2024 in New York City 25.06.2024 / 17:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Newron Pharmaceuticals berichtet vom Investorentag 2024 in New York City Klinische Ergebnisse und neue Erkenntnisse zum Wirkmechanismus lassen auf einzigartige Wirksamkeit in Patienten mit behandlungsresistenter Schizophrenie schließen Führende Schizophrenie-Experten sagen voraus, dass die frühere Anwendung von Evenamide Patien...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.